News
There’s a small industry of professionals who offer to help people of a certain age restructure their affairs so they’ll qualify for Medicaid. The...
Hi, what are you looking for?
iFintechWorld
iFintechWorld
News
Masahiko MoriyamaPresident & Representative Director This is Moriyama from T&D Holdings. Thank you very much for taking the time out of your busy schedules...
News
This article was written by Follow Vasily Zyryanov is an individual investor and writer.He uses various techniques to find both relatively underpriced equities with...
News
This article was written by Follow David A. Johnson is founder and principal of Endurance Capital Management, a New Jersey Limited Liability Company. As...
News
Magellan Midstream Partners, L.P. (NYSE:MMP) 20th Annual Energy Infrastructure CEO & Investor Conference May 23, 2022 8:20 AM ET Company Participants Aaron Milford –...
News
Renters in the Sun Belt may soon see some relief as investors flee the market amid an oversupply of apartments. The number of apartments...
News
New data contained in the annual Workplace Financial Wellness in America report, published by Financial Finesse, paints a picture of broad unmanageable financial stress,...
News
Sprinklr, Inc. (NYSE:CXM) has been one of the victims of the recent tech bear market that brought down many high-performing names. The company went...
News
The numbers: An ongoing and persistent lack of homes in the resale market is pushing more home buyers into new construction, which caused sales...
News
This article was written by A foundation, framework and discipline for optimizing portfolio performance Lawrence is the publisher of The Portfolio Architect. He has...
News
Invesco Dynamic Energy Exploration & Production ETF (NYSEARCA:PXE) is poised to outperform larger, more diverse energy ETFs. One of the key advantages and differentiators...
News
This article is reprinted by permission from NerdWallet. College will cost more for students borrowing during the 2023-24 academic year as federal student loan interest...
News
I knew Zevra Therapeutics (NASDAQ:ZVRA) when it was KemPharm, a commercial stage developer of prodrugs. Zevra, on the other hand, develops treatments for rare...
